BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ImmuneXcite, Inc. Secures $3.58 Million Series B Funding


1/7/2014 11:27:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Lexington , MA, January 6, 2014 — ImmuneXcite, Inc., a biopharmaceutical company focused on developing the next generation of monoclonal antibodies for cancer employing a neutrophils based immunotherapy platform, today announced it has secured $3.58M in second-round financing from new and existing private investors. This is in addition to the $2.42M the company raised in 2011 in its first round of financing and an Accelerator Loan for about $1M from the Massachusetts Life Science Center.

According to Yaniv Bejerano, CEO and Co-Founder, the new investments will largely be devoted to helping move the company’s antibody-carbohydrate mAbXcite conjugates toward an IND (investigational New Drug) filing.

The mAbXcite technology targets cancer cells for destruction by engaging neutrophils, the most abundant and potent white blood cells. Neutrophils provide the body’s first line of defense against fungal and bacterial infections, but are not typically involved in cancer immunotherapy.

ImmuneXcite’s scientific founder discovered a fungal carbohydrate responsible for attracting neutrophils to fungal infections. By chemically conjugating this carbohydrate to cancer-targeting monoclonal antibodies, neutrophils traffic to the site of tumors and initiate tumor destruction.

“We are delighted to add a group of new investors to our existing committed group,” Mr. Bejerano said. “This funding represents an extremely important milestone for ImmuneXcite as we move our program toward IND.”

ImmuneXcite was founded based on research originating from the Whitehead Institute at MIT, where a unique carbohydrate was shown to activate neutrophils. Chemically linking the carbohydrate to monoclonal antibodies to improve their effector function is a bold concept that has been recognized and supported by the Massachusetts Technology Transfer Center, Deshpande Center for Technological Innovation at the Massachusetts Institute of Technology (MIT), the Department of Defense, Massachusetts Life Science Center, National Cancer Institute, and private investors.

ImmuneXcite is headquartered in Lexington, MA.
Contact information:
Please direct all inquiries to PR@immunexcite.com.

Yaniv Bejerano
President and CEO
ImmuneXcite, Inc.
3 Forbes Road
Lexington, MA 02421
O: 781-674-4305
F: 617-963-7500

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES